manageable and correlate with increasing dose and duration of IL-2. Keywords: interleukin-2; breast cancer; stem cell Incubating hematopoietic stem cells with IL-2 in vitro for 24 h generates cytotoxic T cells. When infused into transplantation; immunotherapy patients, these cells may stimulate a graft-versus-tumor (GVT) effect. This clinical trial was designed to assess the ability of IL-2 activated peripheral blood stem cells Hematopoietic stem cell transplantation may improve dis-(PBSC) to reconstitute hematopoiesis, to investigate ease-free survival for many women with stage II-IV breast dose levels and dose-limiting toxicities of IL-2, and to cancer. 1,2 However, dose-escalation of chemotherapy may evaluate clinical results and preliminary laboratory be insufficient to cure some patients, especially patients effects using a combination of IL-2-activated autologous with advanced disease. 3 Novel therapeutic strategies which PBSC followed by IL-2 after transplantation. Sixty-one combine the cytoreductive potential of high-dose chemowomen with stage II-IV breast cancer were treated.
tration of IL-2 results in enhanced cytotoxicity with factor (rhG-CSF) (5 g/kg) was administered subcutaneously 48 h after the administration of priming chemoregression of pulmonary metastasis in a murine melanoma model with chemo-radiotherapy resistant B16 and MCA therapy and continued daily until completion of apheresis. Apheresis was begun once the WBC reached 1 ϫ 10 9 /l. tumors. 13, 19 Possible in vivo anti-tumor effects of IL-2 after transplantation may be due to the generation of endogenous Using a Cobe Spectra Cell Separator (Cobe Laboratories, Lakewood, Colorado, USA) with Anticoagulant Citrate LAK cells, NK cells and other T cell subsets and the induction of cytokines. [21] [22] [23] [24] Dextrose-Formula A (ACD-A) (Baxter Healthcare, Deerfield, IL, USA). Three to four whole blood volumes (10-We initiated a phase I-II clinical trial utilizing the in vitro activation of autologous peripheral blood stem cells 20 l) were processed for each collection and the harvested cells were concentrated to 100 ml. Apheresis was continued (PBSC) with IL-2 followed by the parenteral administration of IL-2 beginning the day of transplantation. After highuntil the following parameters were obtained: (1) 3 ϫ 10 6 CD34 + cells /kg of body weight and (2) 7.5 ϫ 10 8 monodose chemotherapy with cyclophosphamide and carboplatin, women with stage II-IV breast cancer received escalatnuclear cells /kg of body weight. Clonogenic progenitor cell assays were performed for each collection. Concentrated ing doses and increasing duration of IL-2 therapy after transplantation. 25, 26 We describe the clinical results and precell suspensions were cryopreserved in medium consisting of 6% Pentastarch (McGaw, Irvine, CA, USA), 5% DMSO liminary laboratory data from this trial. Patients with breast cancer were chosen since our laboratory data demonstrate (Cryoserv, Research Industries, Salt Lake City, UT, USA), 8% human serum albumin (American Red Cross, Washtumor directed cytotoxicity against tumor breast cancer cell line (MCF-7) using IL-2-activated autologous hematoington DC, USA), and either sterile endotoxin tested bovine pancreatic DNase (Sigma Chemicals, St Louis, MO, USA) poietic stem cells.
or recombinant human DNase (Pulmozyme, Genetech, San Francisco, CA, USA). Cells were frozen in Cryocyte bags (Baxter Healthcare) and stored in liquid nitrogen.
Materials and methods

Patient population
Interleukin-2 activation of PBSC Sixty-one consecutive women with breast cancer who met The procedure has been described previously. 27 Briefly, 24 eligibility criteria were treated from September 1993 until h prior to the PBSC infusion, the harvested cells were June 1995. Patients with high risk stage II (у4 axillary thawed rapidly in a 37°C water bath and incubated for 24 lymph nodes involved with metastatic disease), stage III or h in 5% CO 2 at 37°C in serum-free medium X-VIVO 10 stage IV disease were eligible. Initially, 10 patients with (BioWhittaker, Walkersville, MD, USA) containing gentaresistant disease were treated. micin (50 g/ml), l-glutamine, heparin (50 U/ml) (ElkinsSimm, Cherry Hill, NJ, USA) and IL-2 (6000 IU/ml) (Chiron, Emeryville, CA, USA). Samples from the thawed Eligibility criteria and staging evaluation cell suspension and the IL-2-activated cells were analyzed Patients required a Karnofsky performance status of у80%, for cell count, viability, Gram stain, immunophenotyping, to be 17 years of age and less than 60 years, have adequate cytotoxicity assays and sterility (including testing for bacbone marrow, liver and renal function and no history of teria, fungi, mycoplasma and endotoxin). If Gram stain debilitating cardiac or pulmonary disease. A left ventricular results were negative, activated cells were concentrated to ejection fraction of 50% or greater with a forced expiratory a volume of 200-400 ml using the CS 3000-Plus Blood volume (FEV 1 ) of Ͼ70% and a diffusion capacity Ͼ60%
Cell Separator (Baxter Healthcare). All procedures were were needed. No central nervous system involvement could performed using sterile technique. Approximately one-third exist and negative serologies for Hepatitis B surface antiof the PBSC were not cultured with IL-2 and were stored gen, HIV and HTLV I were required. The protocol received as back-up. institutional review board (IRB) approval and all patients signed an informed consent.
Treatment plan The initial staging evaluation included a complete physical examination, electrocardiogram, audiogram, chest Cyclophosphamide (2000 mg/m 2 ) and carboplatin (600 radiograph, bone scan and computer tomographs of the mg/m 2 ) were administered intravenously over 2 h on days head, thorax, abdomen and pelvis. Laboratory evaluation −5, −4 and −3. 28 MESNA (sodium 2-mercaptoethane included a complete blood count, coagulation profile, renal, sulfonate) and hydration were given as prophylaxis for liver, and thyroid function tests. In patients with measurable hemorrhagic cystitis. The anti-emetic regimen included disease, baseline tumor measurements were obtained by ondansetron, lorazepam, and diphenhydramine. physical examination and/or radiographic studies.
On day 0, after 24 h of culture with IL-2, the activated PBSC were infused over 30-90 min at the patient's bedside.
Peripheral blood stem cell (PBSC) collection and harvest
The design of the clinical trial, including dose-escalation of IL-2 and duration of IL-2 therapy was based on results Prior to priming chemotherapy, a central venous catheter was placed. Either cyclophosphamide (5 g/m 2 ) or paclitaxel obtained in our mouse model. 14, 29 The first five patients were scheduled to receive only IL-2 activated PBSC with-(200-300 mg/m 2 over 24 h) was administered to mobilize PBSC. Recombinant human granulocyte colony-stimulating out post-transplantation IL-2 to monitor engraftment and toxicities. Thereafter, escalation of dose and duration of ILtimes a day) beginning on day −1 and continuing until day 30. With the development of a temperature у38.5°C, broad 2 was performed using a modified Fibonacci scheme (Table  1) . IL-2 administration was initiated on the day of transspectrum antibiotics were initiated and norfloxacin discontinued. Amphotericin B was generally administered empiriplantation. A week of therapy consisted of 5 days of treatment with 2 days of rest. 30, 31 Patients were observed for at cally when patients remained febrile after 48-72 h on broad-spectrum antibiotic therapy. Hyperalimentation was least 30 days after PBSC infusion before proceeding to the next dose level.
initiated if anorexia or nausea/vomiting persisted for 2 or more days. Toxicities were monitored daily and graded as follows: level 0 (no toxicity), level 1 (mild), levels 2 and 3 (moderate), level 4 (severe) and level 5 ( toxic death). Toxicities were reported based on the dose level of IL-2. If
Cytokine support after transplantation severe non-hematologic toxicities occurred during IL-2 therapy (у level 4), IL-2 was suspended until signs or symptoms returned to level 1 (mild) or resolved, often
The initial 50 patients did not receive rhG-CSF in conjunction with IL-2 therapy after transplantation in order to occurring within 24 h. IL-2 was then resumed. If signs and symptoms returned, the patient was removed from the monitor IL-2 toxicity. The final 11 patients received parenteral IL-2 and daily rhG-CSF (5 g/kg/day) beginning study. No further IL-2 therapy was administered to patients with a dose-limiting toxicity that failed to resolve within 72 on day 6 (mean) after transplantation and continuing until the ANC reached 5.0 ϫ 10 9 /l. h. If a patient experienced severe cardiopulmonary toxicity (level 4) with the infusion of IL-2-activated PBSC or if a patient's clinical course was precarious or life-threatening, parenteral IL-2 was not administered after transplantation.
In-hospital clinical monitoring This clinical trial was designed to assess the ability of IL-2-activated PBSC to reconstitute hematopoiesis, to investigate dose levels and dose-limiting toxicities of IL-2, Patients were evaluated daily during hospitalization by physical examination and blood work including a complete and to evaluate clinical results and preliminary laboratory effects using a combination of IL-2-activated autologous blood count with differential and platelet count, electrolytes, liver and renal function tests. Weekly tests included PBSC followed by IL-2 after transplantation. Since one purpose of the trial was to determine the maximally tolercoagulation profile, chest radiograph and electrocardiogram. ated dose of IL-2 after transplantation, we defined MTD as one dose lower then the dose where 33% of the patients Engraftment was defined as an ANC of у0.5 ϫ 10 9 /l for 3 consecutive days. Platelet recovery was defined as a count were removed due to toxicity. The Student's t-test was used for statistical analysis of the laboratory data. Time to of 20 ϫ 10 9 /l or greater for 3 days without transfusion support. Packed red blood cells and single donor platelets were recurrence or progression was calculated from the day of transplantation.
administered if patients were symptomatic or if the hemoglobin level fell below 8.5 g/dl or platelets dropped below 20 ϫ 10 9 /l, respectively. The number of red blood cell and Supportive care platelet units administered was recorded from the day of transplantation until discharge. Patients remained in HEPA-filtered rooms until the absolute neutrophil count (ANC) reached 0.5 ϫ 10 9 /l for 3 consecutive days. At admission, trimethoprim/ sulfamethoxazole (one double strength tablet twice a day)
Clinical monitoring after discharge was administered for Pneumocystis carinii prophylaxis until day −1 and resumed after resolution of neutropenia 2 days each week until day 30. Norfloxacin (400 mg twice a After discharge, patients were evaluated weekly in the outpatient clinic for 1 month and then returned to their referday) was given for gastrointestinal decontamination. Fluconazole (400 mg once a day) was initiated at admission ring oncologist. Evaluation at each clinic visit included a physical examination, a complete blood count, electrolytes, and stopped on day 30. It was suspended if amphotericin B was initiated. Acyclovir was administered (5 mg/kg three liver and renal function tests. Patients were evaluated for response 100 days after transplantation by physical examination, bone scan and CT scans of the thorax, abdomen and Table 1 Outline of IL-2 dose escalation and duration pelvis. Pulmonary function tests and a cardiac gated blood pool scan were also performed to examine regimen-related
Level 1 (n = 5) IL-2 activated PBSC without parenteral IL-2 toxicity. Re-evaluation was done every 6 months thereafter. wall irradiation (stage II and III).
Laboratory analysis of stem cell products Results
Patient demographics Cell recovery, viability and progenitor cell culture
Sixty-one consecutively eligible patients with a mean age of 44.9 years (range 24-59 years) were treated including PBSC obtained from the patients were evaluated for women with stage II (n = 20), stage III (n = 16) or stage viability and cell recovery before and after culturing with IV (n = 25) breast cancer (Table 2) . At the time of trans-IL-2 for 24 h. Trypan blue dye exclusion was used to deterplantation, 35 patients had no evidence of disease (NED) mine viability. To calculate percent recovery, the number (57.4%), 16 patients were in a partial response (PR) of viable cells in culture after 24 h was divided by the (26.2%) and 10 patients had resistant disease (16.4%). number of viable cells originally placed in culture. Progenitor cell cultures were performed by adding 1 × 10 5 mononuclear cells to 1 ml of semisolid methylcellulose medium Engraftment (Stem Cell Technologies, Vancouver, Canada), supAll patients engrafted. The initial 50 patients did not plemented with erythropoietin (1 U/ml) and GM-CSF (200 receive rhG-CSF with IL-2 administration. The final 11 U/ml). One ml cultures were plated in triplicate in 35-mm patients received IL-2 with daily rhG-CSF (5 g/kg) beginPetri dishes and incubated at 37°C in a humidified atmosning on day 6 (mean) after transplantation and continuing phere of 5% CO 2 . Colonies with 40 or more cells were for 6.7 days (mean; range: 2-11 days). For all patients, analyzed on day 14 and identified as burst-forming unit the average number of days required for the ANC to reach erythroid (BFU-E) and colony-forming unit granulocyte-0.5 ϫ 10 9 /l for 3 days was 11.5 days (median: 11 days; macrophage (CFU-GM).
range 8-21 days). The average number of days for the platelet count to remain at 20 ϫ 10 9 /l for 3 days without transfusion support was 11.7 days (median: 10 days; range 7-33 days). The ANC recovery of the 11 patients receiving Phenotyping of the IL-2 activated cells rhG-CSF with IL-2 was 9.5 days (mean; range 8-20 days) compared to 12 days (mean; range 8-21 days) for the 50 Mononuclear cells from pre-and post-activation PBSC patients receiving IL-2 without rhG-CSF. The average samples were obtained by density gradient centrifugation length of stay was calculated for the day of admission for on Hypaque 1077 (Sigma, St Louis, MO, USA). Monochemotherapy and was 25.9 days (range 18-49 days). nuclear cells were incubated with human immune globulin Eosinophilia, defined as Ͼ10% of total white cells comfor 30 min to block nonspecific antigen binding sites.
prised of eosinophils, occurred in 23 patients after transSamples were labeled with phycoerythrin (PE)-tagged antiplantation, beginning after 2-3 weeks of IL-2 therapy. The CD34 (anti-HPCA-2, Becton Dickinson, Mountain View, percentage of eosinophilia ranged from 10 to 81% and CA, USA) and FITC or PE-conjugated antibodies to CD3, sometimes persisted for weeks after discontinuation of IL-CD56, CD19, CD25 (IL-2 receptor) and HLA-DR (Becton 2. The incidence was equally divided between women with Dickinson) and preserved with 1% paraformaldehyde. Data high-risk early stage disease (12 patients) and patients with acquisition was performed within 24 h of staining using stage IV disease (11 patients). two-color analysis on a FACScan (Becton Dickinson).
Blood product support
The average number of packed red blood cells administered In vitro cytotoxicity of the IL-2-activated stem cells to each patient was 7 U/patient (median: 6 U/patient; range: After 24 h of culture with IL-2, cytotoxic activity of the cultured PBSC was measured by a standard 4-h 51 Cr release 2-19 U/patient). The average number of platelet products The pulmonary signs attributed to the capillary leak syndrome were slower to resolve. The dermatologic manifestransfused to each patient was 10 (median: 7 U/patient; range: 1-56 U/patient).
tations sometimes persisted for days despite removal of the IL-2.
Toxicity
Maximal tolerated dose and withdrawal from the study Toxicities are listed according to level of toxicity and dose of IL-2 in Table 3 . The frequency of toxicities was related
In addition to five patients treated on level 1, an additional four of the 61 patients received only IL-2 activated PBSC to dose and duration of IL-2 therapy. One patient experienced a cardiopulmonary arrest on the day of transplanwithout parenteral IL-2 due to the development of acute renal failure (n = 1), small bowel obstruction (n = 1), tation and never received IL-2. This patient required mechanical ventilation and subsequently died due to a noncardiopulmonary arrest (n = 1) or hypotension with the stem cell infusion (n = 1) ( Table 4 ). Nineteen of the 57 traumatic subdural hematoma. Two additional patients experienced transient life threatening toxicities (grade 4) patients (33.3%) receiving post-transplantation IL-2 were removed from the study. Removal from the clinical trial requiring ventilatory support (n = 2). One of these patients did not receive IL-2 after transplantation due to a small correlated with increasing dose and duration of IL-2 therapy. Table 4 demonstrates the number of patients removed bowel obstruction. The second patient was treated on dose level 5 of IL-2 and received 10 of planned 20 days of ILaccording to the dose of IL-2. The development of a temperature Ͼ39°C for greater than 48 h was the most common 2 before developing pulmonary complications.
When comparing the toxicities (Table 3) , the initial side-effect prompting removal of nine patients from the clinical trial. Other factors leading to removal included the group of patients (n = 5) treated on dose level 1 of IL-2 received only the IL-2-activated PBSC without IL-2 after presence of diarrhea (Ͼ3 l/day) persisting for longer than 48 h (n = 2), pulmonary deterioration including the develtransplantation. Table 3 indicates the number of patients (of the total number of patients entered per dose level) experiopment of pleural effusions and decreased arterial oxygenation (n = 3), and the development of a diffuse erythemaencing grade III or IV toxicity. The most common toxicities observed included fever у39°C for 48 h (n = 9), hepatic tous skin rash (n = 1). One patient experienced new onset of atrial fibrillation and symptomatic congestive heart faildysfunction (n = 9), pulmonary deterioration (n = 9), diarrhea (n = 5) and the development of skin rash (n = 14) .
ure and was removed from protocol. Three patients did not meet removal criteria, yet requested removal due to low Nine patients experienced a decrease in liver function with a rise in bilirubin Ͼ2.3 mg/dl, a rise in SGOT Ͼ210 IU/l grade fevers or intermittent episodes of diarrhea. Eleven patients were initially treated at dose level 5 of and/or a rise in the alkaline phosphatase to Ͼ500 IU/l. Six patients developed infiltrates on chest X-ray and a deterio-IL-2 therapy, and then dose level 6 was initiated. Once six of eight patients treated on dose level 6 were removed from ration in arterial oxygenation to 60-70 mm Hg (level 3). Three additional patients required mechanical ventilation protocol due to toxicities, an additional 23 patients were treated on dose level 5. Six of eight patients were removed (level 4) ; two patients were subsequently extubated and discharged from the hospital. The remaining patient died at the highest dose of IL-2 (level 6) due to persistent temperatures (n = 5) or the development of a cardiac arrhyth-(as mentioned above). Fourteen patients developed an erythematous macular or papular skin rash on more than 50% mia (n = 1). The maximal tolerated dose (MTD), defined as the dose level below the level where 33% or more of of their body (level 3). Diarrhea was prevalent with five patients experiencing greater than 3 liters on any 1 day of the patients are removed due to toxicities or side effects, was 6 ϫ 10 5 IU/m 2 /day for 4 weeks. hospitalization (level 3).
The frequency of toxicities increased with the increased dose and duration of IL-2. There were no obvious risk facCell recovery, viability and progenitor cell culture of tors, such as patient age or stage of disease that correlated PBSC products with the occurrence of IL-2-related toxicities. In all patients experiencing hepatic dysfunction and diarrhea, the symp-
The pre-and post-IL-2-activated PBSC samples from 61 patients were analyzed. After 24 h of incubation with ILtoms resolved within days after discontinuing IL-2 therapy. Level 3 = moderate toxicity and level 4 = severe/life-threatening toxicity. a Four patients received IL-2 activated PBSC without parenteral IL-2 due to life-threatening clinical status. SBO = small bowel obstruction; Pt's request = patient's request to be removed from study. One week of therapy consists of 5 days of therapy and 2 days of rest. + cells/kg 15 days after transplantation. 25 Additional laboratory evaluation of immune reconstitution using peripheral blood decreased mildly from the pre-activation samples (mean: 8.6 ϫ 10 6 cells/kg) to the post-activation samples (mean: samples from patients after transplantation is ongoing. 5.3 ϫ 10 6 cells/kg; P = 0.012). 32 There was no change in the number of CFU-GM/kg (mean = 3.52 ϫ 10 5 /kg ± 2.3 )
In vitro cytotoxicity of the IL-2-activated PBSC and BFU-E/kg (mean = 5.8 ϫ 10 5 /kg ± 0.6) when the preand post-IL-2 activated PBSC samples were compared.
Samples of pre-and post-IL-2-activated PBSC were evaluated for cytotoxicity from the first 15 patients treated on this protocol (stage II disease: n =1; stage III disease: n = Phenotype of the IL-2-activated cells 8; stage IV: disease n = 6). When compared to pre-IL-2-activated cells, the activated PBSC demonstrated enhanced PBSC from the first 15 patients activated with IL-2 for 24 h were analyzed by flow cytometry. CD3 + T cells were cytotoxicity against four tumor cell lines including MCF-7 (breast cancer), A375 (melanoma), K562 (CML) and Daudi increased after IL-2 activation and co-expressed the activation markers HLA-DR and CD25 (IL-2 receptor) (Table (NHL) (same E:T ratios) (Figure 1) . The enhanced tumor cell killing of both NK-sensitive and NK-resistant cells 5). There was no significant change in the percentage of Table 5 Description of the surface phenotype of lymphoid cells in pre-and post-IL-2-activated peripheral blood stem cells (n = 15 patient samples) Numbers represent % positive cells for the individual phenotypes (mean ± standard deviation).
Outcome data
Time to progression or relapse was calculated from the day of transplantation. Results according to stage of disease are provided for 60 of the 61 patients, since one patient died during hospitalization (Table 7) . Follow-up period ranges from 12 to 42 months. At the time of transplantation, 10 patients had resistant disease including seven patients with stage IV disease and three patients with stage IIIA disease. When these patients were evaluated, six of the seven stage IV patients relapsed at 13 months after transplantation (median; range 7-18 months) and one patient remains disease free at 14 months. Of the three stage IIIA patients, two patients have relapsed at 7 months (median; range 5-9 months) and the remaining patient remains disease free at 38 months.
Discussion
This phase I-II clinical trial utilized the combination of high-dose chemotherapy with in vitro activation of PBSC with IL-2 followed by parenteral IL-2 beginning the day of transplantation. Toxicities were moderate in severity and increased in frequency with the dose and duration of IL-2 therapy. IL-2 can be safely administered beginning the day number of CD34 + cells/kg and mononuclear cells/kg with no significant change in the numbers of CFU-GM/kg or implicates additional T cell subsets in the killing of these BFU-E/kg. The IL-2-activated PBSC demonstrated malignant cells.
increased tumor directed cytotoxicity against four tumor We also evaluated in vitro cytotoxicity according to stage cell lines with greater cytotoxicity in patients treated in the of breast cancer. IL-2 activated PBSC samples from the adjuvant setting when compared to patients with metastatic first 31 patients were tested against the same three tumor disease. Current laboratory studies are attempting to detercell lines using the same E:T ratios. Patients were grouped mine the phenotype of the IL-2-activated cytotoxic cells. according to stage of disease: stage II and III disease: n = The toxicities associated with IL-2 after transplantation 16; stage IV disease: n = 15. Cytotoxicity of the activated were transient and generally subsided within days after dis-PBSC was lower in patients with metastatic breast cancer continuation of IL-2 therapy. Twenty-three patients could when compared to patients treated in the adjuvant setting not complete the planned course of IL-2 therapy, with 19 (Table 6) . 33 patients experiencing toxicities requiring discontinuation of IL-2. The majority of patients tolerated the full course of Table 6 Comparison of cytotoxicity of the IL-2-activated peripheral IL-2 therapy. Patients who were removed from study generblood stem cell products in patients treated in the adjuvant and metastatic ally received 2-3 weeks of IL-2 before discontinuation. This form of therapy using IL-2-activated autologous PBSC with parenteral IL-2 after transplantation is different n = 31; number of adjuvant patients = 16, number of metastatic disease from LAK cell infusion after transplantation or solely using patients = 15; effector:target ratio 50:1).
IL-2 administration after transplantation. 40, 41 The activated Numbers represent % cytotoxicity. The Student's t-test was used to PBSC, generated from the 24 h incubation with IL-2, differ compare cytotoxicites. adj = adjuvant, met = metastatic.
from LAK cells generated in vivo. Unlike LAK cells, these activated PBSC require a much lower dose of IL-2 for their suggests the biological effects of IL-2 may remain after the course of IL-2 is completed. Finally, the follow-up is too activity and can be generated within 24 h of incubation with IL-2. Additionally, they possess enhanced cytotoxicity short to determine the possible effect of this therapy on relapse and survival in these patients. The overall and disagainst human tumor cell lines when compared to peripheral blood LAK cells. 13 This results in the beneficial effect ease-free survival for these women is comparable to results in the literature. 28 It is encouraging that two patients with of in vitro purging of malignant cells contaminating the PBSC, as well as potential in vivo GVT effects. Animal refractory disease, one patient with stage IIIA disease and one patients with stage IV disease are currently disease free data support the critical need for the combination of in vitro activation of stem cells with IL-2 followed by the adminisat 38+ and 14+ months, respectively. This study demonstrates successful engraftment with ILtration of IL-2 to maintain the in vivo cytotoxic potential of the activated cells. Either process alone is insufficient to 2-activated PBSC after high-dose chemotherapy for women with stage II-IV breast cancer. The regimen is feasible and, generate these cytotoxic effector cells and maintain their efficacy in vivo. 14, 20 although toxicities are common, they are tolerable and correlate with increasing dose and duration of IL-2. Current A few interesting findings were observed from this study. The cause of the lower level of cytotoxicity directed against clinical studies will determine the impact of this therapy on disease-free and overall survival rates utilizing a multithe three tumor cell lines observed in patients with metastatic disease is unknown. Patients with metastatic disease center study randomizing patients to transplantation with IL-2 activation of autologous stem cells and IL-2 after may have an impaired immune system initially, thereby resulting in a dissemination of disease. This may result in transplantation vs high-dose chemotherapy followed by autologous stem cell transplantation. The laboratory studies deceased T cell activation when their PBSC are cultured with IL-2. In addition, there could exist a defective cellular described within the text and additional evaluations continue to examine the existence and mechanisms of IL-2-interaction between the patient's T cells and the malignant cells. Finally, the amount of prior therapy received by induced autologous graft-versus-tumor effects in women with breast cancer undergoing PBSC transplantation. patients with metastatic disease may also contribute to this finding. Secondly, the definition of MTD needs to be addressed. Although the MTD of IL-2 is 6 ϫ 10 5 IU/m 2 /day References for 4 weeks (level 4), moving from level 4 to level 5 (1.8 ϫ 10 5 IU/m 2 /day for 4 weeks) represents a tripling of
